Authors
Categories
  • Budget must ‘build to last’
    by Amar Ambani July 09, 2014 09:07 IST

    At a time when the economic scenario is being furiously debated, conventional wisdom may incline the decision maker to making a choice like ‘either Growth or Fiscal consolidation’, but notwithstanding the tough task at hand, a truly visionary leadership will need to pursue both growth and fiscal consolidation simultaneously.

  • Need to Enhance Liquidity and Funnel Savings into Equity
    by Nirmal Jain July 04, 2014 08:56 IST

    Many a time, our policy makers confuse speculation with manipulation. They put too many restrictions that curb even healthy speculation. I have heard even comments like we should encourage genuine investors but not speculators.

  • NGOs & lack of Coal costs India 2.2% of GDP
    by Amar Ambani June 27, 2014 14:48 IST

    Increasing activism from civil society groups and NGOs have had a deleterious impact on India’s GDP. Opposition to mining and power projects and the concomitant impact on down-stream manufacturing has impacted the economy. Coupled with the stalled coal allocation, the impact on GDP is to the extent of 2.2% in our estimate.

  • RBI policy hints at better days ahead for markets
    by Nirmal Jain June 04, 2014 08:19 IST

    Monetary easing will aid the government's effort to accelerate economy's growth engine as quickly as possible- Nirmal Jain

  • Prepare to live with market uncertainty for another year
    by Amar Ambani May 08, 2013 09:45 IST

    The blog is an extract from my article in Business Standard on the earnings season and the outlook for India Inc in FY14...

  • Time to stay safe
    by Amar Ambani August 13, 2013 10:35 IST

    NSE Nifty may drift towards 5,000 levels on falling market multiples and earnings downgrades.

Back to Top

  • Page
  • 1
 
 
Result Express
IIFL View
  • Thyrocare Tech.

    Thyrocare’s high B2B exposure helps it procure reagent at ~70% discount, thereby protecting margins. The 24% revenue ...

    Buy Reco. Price: 549.25

  • Syngene Intl.

    Syngene is moving up in the CRO value chain by expanding its research capabilities and foraying in API manufacturing in FY20E. ...

    Accumulate Reco. Price: 566.65